“消瘤”调查报道追踪：多款产品下架，有产品宣传依然“露骨”

Core Viewpoint - The article highlights the ongoing issue of false advertising in the sale of health products, particularly those claiming to treat uterine fibroids, and the inadequate regulatory response to these practices [1][20][22]. Group 1: Product Changes and Regulatory Response - Following the publication of a consumer quality report, several products claiming to treat uterine fibroids have been taken down or had their promotional content altered, yet many other products with misleading claims remain available [2][15]. - Specific products, such as the "Anpical Uterine Fibroids capsules," have had their claims modified to remove references to fibroids, while still being sold under different descriptions [3][8]. - The market regulation authorities have intensified efforts to combat false advertising, with significant penalties imposed on violators, including a total of 6,876.91 million yuan in fines since the start of the year [22]. Group 2: Expert Opinions and Recommendations - Experts emphasize the need for a robust credit punishment mechanism to deter businesses from engaging in false advertising, suggesting that violators should be included in a social credit system [1][20]. - There is a call for improved regulatory frameworks to better define and penalize false advertising, as well as for platforms to enhance their vetting processes for sellers [21][22]. - The article notes that consumer awareness and ability to identify false claims are crucial in combating misleading advertisements, with recommendations for consumers to retain evidence of promotional materials [20][21].